Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: J Cyst Fibros. 2021 Jan 30;20(3):381–387. doi: 10.1016/j.jcf.2021.01.007

Figure 2. Risks of continuation or discontinuation of highly effective modulator treatment (HEMT) during pregnancy.

Figure 2.

The unknown risk to the fetus includes the potential risk of the development of cataracts based on demonstration of cataract formation in juvenile rats who were administered ivacaftor.(56)